Limb-girdle muscular dystrophy gene therapy data lift Sarepta

Early data from a Phase I/II study of SRP-9003 to treat a form of limb-girdle muscular dystrophy showed the gene therapy led to functional improvements in all three patients in a low-dose cohort at nine months. Results from a planned

Read the full 407 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE